DK3463345T3 - Farmaceutiske kombinationer - Google Patents
Farmaceutiske kombinationer Download PDFInfo
- Publication number
- DK3463345T3 DK3463345T3 DK17807555.2T DK17807555T DK3463345T3 DK 3463345 T3 DK3463345 T3 DK 3463345T3 DK 17807555 T DK17807555 T DK 17807555T DK 3463345 T3 DK3463345 T3 DK 3463345T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical combinations
- pharmaceutical
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345389P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035653 WO2017210538A1 (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3463345T3 true DK3463345T3 (da) | 2023-01-09 |
Family
ID=60477982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17807555.2T DK3463345T3 (da) | 2016-06-03 | 2017-06-02 | Farmaceutiske kombinationer |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10485788B2 (enExample) |
| EP (1) | EP3463345B1 (enExample) |
| JP (2) | JP6805336B2 (enExample) |
| KR (1) | KR102439911B1 (enExample) |
| CN (1) | CN109890386B (enExample) |
| AU (1) | AU2017275650B2 (enExample) |
| BR (1) | BR112018074941A2 (enExample) |
| CA (1) | CA3026361A1 (enExample) |
| CL (1) | CL2018003421A1 (enExample) |
| CO (1) | CO2019000010A2 (enExample) |
| CR (1) | CR20190002A (enExample) |
| DK (1) | DK3463345T3 (enExample) |
| FI (1) | FI3463345T3 (enExample) |
| HU (1) | HUE060653T2 (enExample) |
| IL (1) | IL263431A (enExample) |
| MA (1) | MA45187A (enExample) |
| MX (1) | MX387795B (enExample) |
| PH (1) | PH12018502549A1 (enExample) |
| PL (1) | PL3463345T3 (enExample) |
| PT (1) | PT3463345T (enExample) |
| RU (1) | RU2759669C2 (enExample) |
| SG (1) | SG11201810793XA (enExample) |
| SI (1) | SI3463345T1 (enExample) |
| UA (1) | UA125436C2 (enExample) |
| WO (1) | WO2017210538A1 (enExample) |
| ZA (1) | ZA201900019B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3463345T3 (fi) | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä | |
| EP3515446B1 (en) * | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| US12187703B2 (en) | 2019-05-13 | 2025-01-07 | Novartis Ag | Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer |
| BR112022004670A2 (pt) | 2019-10-11 | 2022-06-07 | Hoffmann La Roche | Dispositivo de computação e método implementado por computador |
| WO2021163072A1 (en) * | 2020-02-10 | 2021-08-19 | Cedars-Sinai Medical Center | Method of treating pancreatic cancer |
| JP7288220B2 (ja) | 2021-03-29 | 2023-06-07 | ダイキン工業株式会社 | モータ、送風装置、および冷凍装置 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| DK2324008T3 (da) | 2008-07-24 | 2012-07-23 | Nerviano Medical Sciences Srl | Diarylpyrazol som protein kinase inhibitorer |
| JP5527878B2 (ja) * | 2009-07-30 | 2014-06-25 | トムソン ライセンシング | 表示装置及び音声出力装置 |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| EP2718485A4 (en) * | 2011-06-07 | 2015-05-06 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| JP6150813B2 (ja) * | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| CN103945831A (zh) | 2011-11-23 | 2014-07-23 | 诺华股份有限公司 | 医药制剂 |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| RS58734B1 (sr) | 2012-08-07 | 2019-06-28 | Novartis Ag | Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor |
| BR112015008623B1 (pt) | 2012-10-19 | 2022-10-25 | Novartis Ag | Processos de preparação de (2-hidroxietióxi)-amida do ácido 6-(4-bromo-2-fluorfenilamino) -7-flúor-3-metil-3h-benzoimidazol-5-carboxílico cristalizado e seus intermediários |
| CA2889530A1 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
| MY181085A (en) | 2013-03-21 | 2020-12-17 | Novartis Ag | Combination therapy |
| CN105392763A (zh) * | 2013-07-18 | 2016-03-09 | 株式会社大赛璐 | 氧化物的制造方法 |
| US20150087279A1 (en) * | 2013-09-20 | 2015-03-26 | Better Mousetrap, LLC | Mobile accident processing system and method |
| KR20160088884A (ko) * | 2013-12-12 | 2016-07-26 | 노파르티스 아게 | 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물 |
| CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
| WO2016155670A1 (zh) * | 2015-04-01 | 2016-10-06 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
| US20170027951A1 (en) | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| FI3463345T3 (fi) | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä |
-
2017
- 2017-06-02 FI FIEP17807555.2T patent/FI3463345T3/fi active
- 2017-06-02 MX MX2018014973A patent/MX387795B/es unknown
- 2017-06-02 BR BR112018074941-9A patent/BR112018074941A2/pt not_active Application Discontinuation
- 2017-06-02 CA CA3026361A patent/CA3026361A1/en active Pending
- 2017-06-02 JP JP2019515782A patent/JP6805336B2/ja active Active
- 2017-06-02 UA UAA201813074A patent/UA125436C2/uk unknown
- 2017-06-02 WO PCT/US2017/035653 patent/WO2017210538A1/en not_active Ceased
- 2017-06-02 SG SG11201810793XA patent/SG11201810793XA/en unknown
- 2017-06-02 MA MA045187A patent/MA45187A/fr unknown
- 2017-06-02 SI SI201731293T patent/SI3463345T1/sl unknown
- 2017-06-02 CR CR20190002A patent/CR20190002A/es unknown
- 2017-06-02 RU RU2018146812A patent/RU2759669C2/ru active
- 2017-06-02 EP EP17807555.2A patent/EP3463345B1/en not_active Revoked
- 2017-06-02 HU HUE17807555A patent/HUE060653T2/hu unknown
- 2017-06-02 KR KR1020187037798A patent/KR102439911B1/ko active Active
- 2017-06-02 CN CN201780048857.2A patent/CN109890386B/zh active Active
- 2017-06-02 DK DK17807555.2T patent/DK3463345T3/da active
- 2017-06-02 PT PT178075552T patent/PT3463345T/pt unknown
- 2017-06-02 PL PL17807555.2T patent/PL3463345T3/pl unknown
- 2017-06-02 AU AU2017275650A patent/AU2017275650B2/en not_active Ceased
-
2018
- 2018-11-30 CL CL2018003421A patent/CL2018003421A1/es unknown
- 2018-12-03 IL IL263431A patent/IL263431A/en unknown
- 2018-12-03 US US16/208,172 patent/US10485788B2/en active Active
- 2018-12-03 PH PH12018502549A patent/PH12018502549A1/en unknown
-
2019
- 2019-01-02 CO CONC2019/0000010A patent/CO2019000010A2/es unknown
- 2019-01-02 ZA ZA2019/00019A patent/ZA201900019B/en unknown
- 2019-09-24 US US16/580,505 patent/US11376239B2/en active Active
-
2020
- 2020-12-03 JP JP2020201152A patent/JP2021054832A/ja active Pending
-
2022
- 2022-05-16 US US17/745,136 patent/US20230044943A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3405050T3 (da) | Børnesikret snusbeholder | |
| EP3440949A4 (en) | FLAVOR INHALER | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| EP3446605A4 (en) | HAND VACUUM | |
| DK3436823T3 (da) | Antigen-array | |
| DK3335532T3 (da) | Tandharve | |
| DK3402792T3 (da) | Quinolin-2-on-derivater | |
| EP3424940A4 (en) | Radiolabeled drug | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3463345T3 (da) | Farmaceutiske kombinationer | |
| EP3402022A4 (en) | GRAB WIRE | |
| DK3445708T3 (da) | Stigbøjle | |
| EP3402021A4 (en) | GRAB WIRE | |
| EP3437644A4 (en) | MEDICINE | |
| DK3509963T3 (da) | Pallecontainer | |
| DK3452590T3 (da) | Plademagnet | |
| DK3528829T3 (da) | Bacitracin-alginat-oligomer-konjugater | |
| DK3575238T3 (da) | Pallecontainer | |
| EP3527216A4 (en) | Medicine | |
| EP3399976C0 (en) | BENZOTHIAZOLE AMPHOPHILES | |
| DE112017000734A5 (de) | Glycolsensor | |
| DE112017006386A5 (de) | Schraubarbeitszylinder | |
| DK3323708T3 (da) | Bovfender | |
| EP3646865A4 (en) | MEDICINE | |
| DK3452587T3 (da) | Penicillin-g-acylaser |